MarketCap
Facebook
X
TelegramAnnual report 2024
added 12-13-2025
Cellectis S.A. ROE Ratio 2011-2025 | CLLS
Annual ROE Ratio Cellectis S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -26.25 | -32.41 | -19.62 | -36.51 | -23.38 | -7.79 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -7.79 | -36.51 | -24.33 |
Quarterly ROE Ratio Cellectis S.A.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -13.76 | -27.53 | -27.53 | -13.76 | -24.15 | -20.78 | -20.78 | -10.39 | -19.43 | -18.09 | -18.09 | -9.04 | -9.04 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -9.04 | -27.53 | -17.88 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
-68.71 | $ 4.85 | 3.03 % | $ 805 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-84.9 | $ 3.24 | -0.46 % | $ 250 M |  USA |
 |
AlloVir
ALVR
|
-51.87 | - | 4.14 % | $ 49.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
-507.47 | $ 1.06 | -6.19 % | $ 293 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 216.6 | -1.74 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
-36.22 | $ 3.14 | -4.56 % | $ 7.55 B |  Australia |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
BioVie
BIVI
|
-92.27 | $ 1.37 | -5.21 % | $ 2.02 M | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-288.19 | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
1.11 | $ 93.82 | -1.04 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-40.17 | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
21.78 | $ 26.28 | 3.99 % | $ 1.27 B | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
-38.95 | $ 9.56 | - | $ 140 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-144.96 | $ 0.27 | -7.19 % | $ 588 M |  Israel |
 |
Arena Pharmaceuticals
ARNA
|
-91.56 | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
-531.22 | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
Catalyst Biosciences
CBIO
|
540.06 | $ 13.75 | -2.41 % | $ 905 M | USA |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
12.83 | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
16.2 | $ 545.68 | -3.3 % | $ 41.3 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-71.51 | $ 2.37 | 3.04 % | $ 14.9 M | USA |
 |
AstraZeneca PLC
AZN
|
20.44 | $ 91.17 | 1.49 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-57.34 | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
10.1 | $ 8.9 | -1.22 % | $ 1.45 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
-19.35 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
114.5 | $ 11.36 | -1.52 % | $ 735 M | USA |
 |
Biogen
BIIB
|
9.76 | $ 173.96 | -0.08 % | $ 25.3 B | USA |
 |
Abeona Therapeutics
ABEO
|
-365.49 | $ 5.09 | -5.13 % | $ 109 M | USA |
 |
Celldex Therapeutics
CLDX
|
-21.13 | $ 27.29 | -0.8 % | $ 1.76 M | USA |
 |
ADiTx Therapeutics
ADTX
|
-8126.35 | $ 1.65 | -26.34 % | $ 21.7 K | USA |
 |
Cellectar Biosciences
CLRB
|
282.15 | $ 3.41 | -5.8 % | $ 41.7 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-1239.35 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-69.02 | - | -7.31 % | $ 87 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Завод ДИОД
DIOD
|
3.1 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
-51.75 | - | - | - | Russia |